Loading...
NPI 1336556745 · Tulsa, OK · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Certigen Laboratory, LLC is a clinical medical laboratory provider located in Tulsa, Oklahoma. This profile covers 27 Medicare and 46 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Certigen Laboratory, LLC |
| Address | 9309 S Toledo Ave |
| City | Tulsa |
| State | OK |
| ZIP | 74137 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 17, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $284.3K |
CERTIGEN LABORATORY, LLC shows a pronounced Medicare-weighted revenue profile: reported total Medicare revenue is $2.1M versus total Medicaid revenue of $284.3K, indicating Medicare is the dominant payer by scale for this entity. The provider is not single-payer but relies far more heavily on Medicare cashflow in absolute terms.
Revenue concentration is acute on a few codes for Medicare: the precomputed top 3 Medicare codes by revenue account for 80.9% of this provider's total Medicare revenue, with G0483 alone representing $1.4M (68.2% of Medicare revenue). This concentration signals that definitive drug testing is the primary Medicare revenue driver and that fluctuations in utilization or reimbursement for these few codes would meaningfully affect overall Medicare revenues.
On Medicaid the concentration is similarly compact: the precomputed top 3 Medicaid codes by revenue account for 80.7% of this provider's total Medicaid revenue, and 80307 contributes $168.8K (58.9% of Medicaid revenue). Medicaid revenue is therefore also heavily dependent on drug-testing services, with a small set of CPT/HCPCS codes producing the majority of state-level payments.
The provider’s code mix and volumes indicate a laboratory operation primarily focused on drug testing and molecular infectious diagnostics: Medicare top codes include G0483 ($1.4M), 80307 ($170.4K), and 87798 ($96.3K), while Medicaid top codes include 80307 ($168.8K), G0483 ($42.5K), and U0003 ($19.9K). The presence of high-volume definitive drug-testing codes (G0483, G0481, G0482) together with both presumptive screens (80307) and multiple nucleic acid amplification test codes (e.g., 87798, 87502, ) points to a mixed-service lab that pairs toxicology services with infectious disease molecular testing.
CERTIGEN’s competitive standing for its primary Medicare code is strong at the national level: G0483 ranks #17 of 1063 providers nationally (98th percentile; notably above typical national volume for this code), marking it as a major national participant in high-complexity definitive drug testing. By contrast some specialty or high-dollar tests have limited activity—81455 shows modest volume (18 claims, $51.5K) and ranks #30 of 36 providers nationally (14th percentile; typical, unremarkable volume for this code)—indicating selective engagement in genomic panels.
State-level positioning on Medicaid reinforces strength in drug testing: Medicaid G0483 ranks #2 of 16 providers in-state (93th percentile; typical, unremarkable volume for this code) and 80307 ranks #23 of 103 providers in-state (78th percentile; typical, unremarkable volume for this code). These ranks suggest the provider is a significant in-state supplier for definitive drug testing while maintaining typical volumes for presumptive screens relative to peers.
Operational tenure and scale: the NPI was enumerated on 2014-07-17 (~12 years ago), which, together with multi-thousand claim counts on key codes (e.g., 5.9K claims for G0483 on Medicare; 5K claims for 80307 on Medicaid), indicates an established laboratory presence with sustained case flow in both toxicology and molecular testing lines. This longevity and volume profile suggest operational stability and likely existing infrastructure for high-throughput testing.
There are clear statistical outlier signals in the Medicare mix that merit attention: G0483 is described as “notably above typical national volume for this code” and 87502 appears at the 99th percentile (ranks #50 of 3547 providers nationally; 99th percentile; typical, unremarkable volume for this code), while several other molecular test codes fall into mid-range percentiles. These labels indicate the provider is an unusually large national submitter for certain definitive drug and some molecular respiratory testing codes, while other advanced testing like genomic panels remains limited in scale.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
27 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,900 | $240 | $1.4M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,790 | $60 | $170.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,830 | $30 | $96.3K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 620 | $150 | $94.5K |
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 20 | $2,860 | $51.5K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 1,440 | $30 | $49.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 640 | $70 | $43.9K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 300 | $90 | $28.2K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 560 | $30 | $19.1K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 260 | $70 | $17.7K |
Showing 1–10 of 27
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 27 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
27 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 3 | 10 | 11,000 | $30 | $672.7K |
| 87798 | 9 | 40 | 1,090 | $30 | $188.7K |
| 87801 | 11 | 20 | 640 | $70 | $148.4K |
| G0483 | 1 | 30 | 140 | $240 | $134.2K |
| G0482 | 41 | 40 | 310 | $190 | $108.9K |
| U0004 | 7 | 10 | 210 | $70 | $94.2K |
| 87481 | 13 | 40 | 360 | $30 | $70.3K |
| 81455 | 2 | 10 | 20 | $2,790 | $58.7K |
| G0481 | 3 | 30 | 90 | $150 | $42K |
| 87541 | 3 | 10 | 110 | $30 | $29.4K |
Showing 1–10 of 27
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
46 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 4,960 | $30 | $168.8K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,250 | $10 | $42.5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 870 | $20 | $19.9K |
| 80356 | The lab analyst measures the amount of or detects the presence of heroin metabolite in the patient specimen. | 470 | $10 | $5.1K |
| 80361 | The lab analyst measures the amount of or detects the presence of one or more opiates, narcotic analgesics that depress the central nervous system, in the specimen. | 440 | $10 | $4.4K |
| 80324 | The lab analyst measures the amount of or detects the presence of one or two amphetamines, a central nervous system stimulant in a patient specimen. | 470 | $10 | $3.8K |
| 80354 | The lab analyst measures the amount of or detects the presence of fentanyl in the patient specimen. | 470 | $10 | $3.3K |
| 80335 | The lab analyst measures the amount of or detects the presence of one or two tricyclic and other cyclical antidepressants, which are psychiatric medications, in a patient specimen. | 340 | $10 | $3.1K |
| 80357 | The lab analyst measures the amount of or detects the presence of ketamine and norketamine in the patient specimen. | 470 | $10 | $2.8K |
| 80359 | The lab analyst measures the amount of or detects the presence of methylenedioxyamphetamines in the patient specimen. | 470 | $10 | $2.8K |
Showing 1–10 of 46
How this provider's Medicaid billing volume and revenue compare to other Oklahoma providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Oklahoma median
46 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 6 | 20 | 60 | $60 | $404.2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 9 | 30 | 120 | $60 | $243.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 15 | 50 | 330 | $80 | $238.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 23 | 100 | 630 | $50 | $197.2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 39 | 50 | 280 | $50 | $81.5K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 27 | 110 | 160 | $80 | $69.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 10 | 90 | $70 | $69.3K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 120 | $50 | $61.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 10 | 30 | 370 | $20 | $60.1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 17 | 30 | 230 | $20 | $43.2K |
Showing 1–10 of 46
Other providers in the same ZIP code as Certigen Laboratory, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.